Abstract. The mechanisms whereby mutant gene expression triggers neurodegeneration are poorly understood but have generally been attributed to translated gene products. We now demonstrate direct neuropathic effects of untranslated RNA on cultured motor neurons. We show that expression of untranslated light neurofilament (NF-L) RNA sequence in the 3ЈUTR of an EGFP transgene (pEGFP/NF-L RNA) or in a separate expression vector (pRc/NF-L RNA) causes dose-dependent, neuronspecific motor neuron degeneration. Neither unfused EGFP protein (pEGFP/wt) nor EGFP-tagged NF-L protein (pEGFP/NF-L protein) has similar neuropathic effects. The findings are the first demonstration of a direct RNA-mediated neurotoxic effect. Moreover, the resulting neuropathological changes show that untranslated RNA can lead to early degeneration of neuritic processes and accumulations of ubiquitinated aggregates in the perikarya and nuclei of degenerating motor neurons. The latter findings are hallmark neuropathological features of neurodegenerative diseases and their occurrence as a result of altered RNA expression raises the prospects of an RNA-mediated component in the pathogenesis of neurodegenerative states.
INTRODUCTION
Insights into the nature of neurodegeneration have been advanced by the identification of genetic mutations causing neurodegenerative diseases and the ability of mutant gene products to model neurodegenerative states in transgenic mice. However, the mechanisms whereby expression of mutant genes leads to neurodegeneration remain poorly understood. In many instances, mutant genes have a gain-of-adverse effect as evidenced by their pattern of dominant inheritance and ability to elicit neuropathic changes when expressed in transgenic mice. While it is generally assumed that neuropathic changes are due to expression of mutant protein, it is also possible that adverse effects could arise from expression of RNA. The presence of RNA-mediated neuropathic effects, albeit unexpected, could provide important perspectives and novel insights into the initiating cause and downstream pathways leading to a neurodegenerative state.
Regulation of neurofilament (NF) gene expression is a critical determinant in establishing and maintaining the shape, size, and conductive properties of axons (1) and is therefore a major pathway in regulating and maintaining neuronal structure and function. Altering levels of NF expression by itself can cause neurodegeneration in transgenic mice (2, 3) and can alter the neuropathic effects of other gene products in transgenic mice (4) (5) (6) (7) (8) . Levels of NF expression are also selectively altered in neurons-atrisk in neurodegenerative disease (9) (10) (11) , in transgenic models of motor neuron disease (11) (12) (13) , and in spontaneous motor neuron degeneration in Wobbler mice (14) . Hence, pathways regulating levels of NF expression may be important for maintaining neuronal homeostasis as well as the cytoskeletal structural integrity of large differentiated neurons.
Neuropathic effects due to altered NF expression were initially observed in motor neurons of mice expressing high levels of NF-L (2) or NF-H (3) transgenes or low levels of a mutant NF-L transgene (15) . Transcripts from the latter transgene contained mutant RNA binding sites of trans-acting factors, raising the possibility that interactions of NF-L transcripts with RNA-binding proteins could give rise to motor neuron degeneration (16) (17) (18) . This hypothesis has been supported by reproducing a motor neuron phenotype in transgenic mice expressing mutant or wild-type NF-L sequence in the 3ЈUTR of an EGFP reporter transgene (19) .
The strength of transgenic models is, however, their ability to reproduce neuropathic phenotypes, not in addressing causal mechanisms of underlying neurodegenerative states. The latter deficiency is due in part to the static nature by which neuropathological correlates of dysfunctional states can be examined in live animals. Moreover, it is unclear whether neuropathic effects are mediated solely and directly by expression of the transgene in neurons-at-risk, whether the effects are immediate, or delayed or modified by transgene expression in other cell types. Exogenous gene expression in transgenic models may also elicit complex compensatory alterations in genome expression that modulate a neuropathic response. These questions have been raised as to the nature of motor neuron degeneration due to expression of mutant superoxide dismutase-1 (SOD-1) transgenes where neurodegeneration may require transgene expression in motor neurons and in glia (20) and may not occur when the transgene is only expressed in neurons (21) or in glia (22) . Neuropathic effects may also require transgene expression in other cell types (23) or be modified by interactions with neighboring cells (24) (25) (26) .
Primary neuronal cultures provide a setting for direct, immediate, and continuous examination of the adverse effects of neuropathic gene expression. Introduction of transgenes into cultured motor neurons also enables assessment of whether neuropathic effects arise from translated or untranslated products of gene expression. Moreover, neuronal cultures from embryonic murine spinal cord not only retain the postmitotic status of differentiated neurons but also provide populations of motor and sensory neurons for side-by-side evaluation of their respective susceptibilities to neuropathic effects (23, 27) , or to study neuropathic effects on motor neurons (28) (29) (30) (31) (32) (33) (34) in the context of a mixed population of neuronal and nonneuronal cells.
This study has examined the neuropathic effects of NF-L transgenes in primary neuronal cultures and has shown that neuropathic effects arise directly from expression of untranslated NF-L RNA in motor neurons. Neuropathic effects are reproduced when untranslated NF-L RNA is expressed in a heterologous EGFP reporter transgene or when coexpressed from a separate expression vector. More importantly, RNA-mediated neuropathic effects are dose-dependent, neuron-specific, and lead to accumulations of ubiquitinated aggregates in perikarya and nuclei of degenerating motor neurons. These are hallmark pathological features of many neurodegenerative diseases and their linkage to RNA-mediated toxic effects raises the prospects of an RNA-mediated component in the pathogenesis of neurodegeneration. The ability to trigger RNA-mediated toxic effects in cultured motor neurons is an important step toward elucidating the potential role of RNA and RNA-binding proteins in the pathogenesis of a neurodegenerative state.
MATERIALS AND METHODS

DNA Constructs
NF-L sequence was placed in pEGFP/C1 or pEGFP/C2 expression vectors (Clontech, Palo Alto, CA) to visualize transgene expression in targeted cells. To study the effects of untranslated NF-L RNA, a 680-nucleotide (nt) fragment from ϩ1482/ϩ2161 of mouse NF-L cDNA was inserted into the BamH1/HindIII sites of pEGFP/C1 with stop codons immediately upstream of the NF-L sequence to ensure that the NF-L sequence is transcribed but not translated. This EGFP transgene expressing untranslated NF-L sequence is referred to as pEGFP/ NF-L RNA. Western blots were conducted in a previous study (19) to show that the same-sized 29-kDa EGFP protein is expressed by pEGFP/NF-L RNA and by an unfused EGFP expression vector (pEGFP/wt). To study the effects of NF-L protein on targeted neurons, full-length coding region of NF-L cDNA was amplified by PCR from a mouse brain cDNA library and fused in frame to the C-terminus of the EGFP coding region in the pEGFP/C2 vector. This transgene expressing EGFPtagged NF-L protein is referred to as pEGFP/NF-L protein. To assess the effects of untranslated NF-L sequence when expressed in a separate expression vector, the 680-nt NF-L sequence (ϩ1482/ϩ2161) and upstream stop codons were amplified by PCR and cloned into pRc/CMV (Invitrogen, Carlsbad, CA). This transgene is referred to as pRc/NF-L RNA. The 680-nt sequence of NF-L (ϩ1482/ϩ2161) with upstream stop codon and 36-nt c-myc insert (19) was also amplified by PCR and cloned into pRc/CMV. This transgene with c-myc insert is referred to as pRc/NF-L RNA/c-myc. All DNA constructs were fully sequenced. They are shown schematically in Figure 1 .
Neuronal Cultures
Primary cultures of dissociated spinal cord were prepared from 12.5 to 13.5 day CD1 mouse embryos by the methods of Durham (27, 30, 35, 36) . In brief, spinal cords with dorsal root ganglia attached were dissected from embryos, dissociated with trypsin, and plated on 12-mm glass coverslips (Fisher Scientific, Pittsburgh, PA) precoated with poly-L-lysine (Sigma-Aldrich, St. Louis, MO) and Matrigel matrix (Becton Dickinson Labware, Bedford, MA) at a density of 200,000 cells per well in 24-well culture dishes. Cells were grown in modified N3 medium and treated with 1.4 g/ml cytosine arabinoside (Sigma-Aldrich) after 4 to 6 days to minimize growth of nonneuronal cells. Cultures were transfected at 7 to 9 days following dissociation and subjected to microinjection after 6 to 8 weeks in vitro.
Microinjection of Motor and Sensory Neurons
Microinjections were conducted using a Zeiss Axiovert-10 microscope, Eppendorf 5170 micromanipulator, and Eppendorf 5242 microinjector. DNA constructs for microinjection were purified by CsCl gradient ultracentrifugation and clarified by spinning at 12,000 g for 15 min. Constructs containing EGFP cDNAs (50 or 200 ng/l) were microinjected into neuronal nuclei as unmodified expression vector (pEGFP/wt) or chimeric constructs fused to NF-L coding region (pEGFP/NF-L protein) or untranslated NF-L sequence (pEGFP/NF-L RNA). pRc/CMV expression vectors (200 ng/l) containing unmodified NF-L sequence (pRc/NF-L RNA), NF-L sequence with a 36-bp c-myc insert (pRc/NF-L RNA/c-myc), or empty vector (pRc/wt) were coinjected into neuronal nuclei with pEGFP/wt vector (50 ng/ l). Nuclear injections were monitored by phase microscopy by the pulsatile expansions of nuclear profiles upon release of injectant from the capillary tip. Microinjected neurons were subsequently identified by the presence of EGFP fluorescence or anti-EGFP immunoreactivity. It was determined in preliminary experiments that 50 ng/l pEGFP/wt was sufficient for identifying microinjected neurons.
Transfection of Motor Neurons
Plasmid constructs for transfection were prepared using Plasmid Maxi Kit (Qiagen, Valencia, CA). After 7 to 9 days in 
Assessment of Neuronal Viability
Daily counts of motor neurons containing EGFP fluorescence were conducted on each coverslip during an 8-day interval and normalized to the numbers present on day 1, according to the method of Durham (27) . There were 15 to 60 fluorescent motor neurons per coverslip at 24 h (day 1) following microinjection and 40 to 200 fluorescent motor neurons per coverslip following transfection. Each experiment was performed in triplicate.
Fluorescence Microscopy
Motor neurons were visualized by phase and fluorescence microscopy using a Nikon TE300 inverted microscopy. Sequential changes in number and morphology of fluorescent motor neurons were assessed by direct visualization and were also recorded on digital camera images of the same coverslip areas taken daily over an 8-day period. The positioning of motor neurons on coverslips and the distinctive disposition of EGFP fluorescence in different motor neurons enabled identification of the same neurons following fixation and detection of EGFP fluorescence or anti-EGFP immunoreactivity. 
Immunocytochemistry
Cultures were fixed for 1 hour at 4ЊC in 4% paraformaldehyde and permeabilized in 0.5% Triton X-100. Fixed cells were incubated with 1:200 dilution of goat polyclonal anti-NF-L antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or 1:500 dilution of rabbit polyclonal anti-ubiquitin antibody (DAKO Corp, Carpinteria, CA) overnight at 4ЊC, then incubated with anti-goat IgG or anti-rabbit IgG secondary antibodies conjugated with Texas-Red (Vector Laboratories, Burlingame, CA), and mounted in VECTASHIELD mounting medium with DAPI (Vector Laboratories). Anti-ubiquitin and anti-NF-L immunoreactivities were visualized in DAPI-stained cells by confocal microscopy using a Bio-Rad 1024 UV laser scanning confocal microscope. EGFP immunoreactivity was detected by incubating cells with 1:250 dilution of Living Color anti-GFP antibody (Clontech) overnight at 4ЊC, then using a biotinylated secondary antibody, ABC reagents, and DAB substrate (Vector Laboratories) and counterstaining with hematoxylin.
RESULTS
EGFP Expression in Targeted Motor Neurons
Motor neurons in cultures of E13 mouse spinal cord were readily identified by the large size and configuration of their nuclei, perikarya, and neurites amidst a background of multiple interlacing processes of smaller neuronal and nonneuronal cells ( Fig. 2A) . Individual and clusters of primary sensory neurons were recognized by their large nuclei, prominent nucleoli, round to ovoid perikarya ( Fig. 2B ) with unipolar neurites, and distally branching neuritic processes. Motor neurons underwent progressive enlargement and stabilization in vitro and became optimal for microinjections after 6 to 8 weeks, as previously reported (36) . Expression of an EGFP reporter transgene enabled monitoring of brightly fluorescent neurons for at least a week following transfection or microinjection (see below). At the same time, detection of the fluorescent marker provided assurance of transcription, posttranscriptional processing, and translation of gene products from experimental and control expression vectors.
In order to compare the neuropathic effects of translated and untranslated NF-L sequence on motor neurons in primary culture, chimeric EGFP expression vectors were constructed containing the full-length NF-L coding region fused in frame to the C-terminus of the EGFP protein (pEGFP/NF-L protein) or containing untranslated NF-L sequence in the 3ЈUTR of the transgene (pEGFP/ NF-L RNA), as shown in Figure 1 . Stop codons were placed immediately upstream of the NF-L sequence in pEGFP/NF-L RNA to assure that the NF-L sequence in this construct is transcribed but not translated. pEGFP/ NF-L RNA was the same transgene whose expression caused motor neuron degeneration in transgenic mice (19) . Visualization of EGFP fluorescence enabled identification and study of targeted motor and sensory neurons in spinal cord cultures.
To examine the effects of the different transgenes on NF-L expression, EGFP fluorescence (Fig. 3A , C, E) was compared with NF-L immunofluorescence (Fig. 3B , D, F) in targeted motor neurons. Microinjection of an unfused EGFP expression vector (pEGFP/wt) led to rapid and widespread fluorescence throughout nuclei, perikarya, and neuritic processes of motor neurons (Fig. 3A, B) . Unlike unfused EGFP protein, EGFP-tagged NF-L protein (pEGFP/NF-L protein) was incorporated into the neuronal cytoskeleton as evidenced by the lack of nuclear EGFP fluorescence (Fig. 3C, D, and neuritic processes (Fig. 3C, D, arrows) . Microinjection of the EGFP transgene with untranslated NF-L RNA in the 3ЈUTR (pEGFP/NF-L RNA) resulted initially in rapid and widespread EGFP fluorescence, similar to that seen following injection of control pEGFP/wt vector. After 3 days, however, there was extensive fragmentation of neurites of motor neurons containing EGFP fluorescence (Fig. 3E) , as described below. Motor neurons were not diminished when cotransfected with pEGFP/wt and an empty pRc/CMV expression vector (pRc/wt), as shown in Figure 4B . However, cotransfection with a pRc/CMV vector containing untranslated NF-L sequence (pRc/NF-L RNA) resulted in a 50% loss of transfected neurons over a 7-day period. An intermediate level of motor neuron loss occurred when cotransfected pRc/NF-L RNA transgene was reduced from 3 to 1 g. A similar loss of motor neurons occurred when cotransfected with the pRc/NF-L RNA/c-myc transgene (Fig. 4C) . Although the pRc/NF-L RNA/c-myc transgene caused a greater loss of motor neurons than the pRc/NF-L RNA transgene at low levels of transgene expression, the enhanced neuropathic effects of the c-myc inserts observed in transgenic mice (19) was not reproduced at higher levels of transgene expression in vitro.
EGFP Fluorescence in Degenerating Motor Neurons
The earliest neuropathological changes due to expression of untranslated NF-L RNA were detected as a distalto-proximal progression of varicose swelling, fragmentation, and loss of neurites (Fig. 5B, C) compared to control motor neurons (Fig. 5A ). These changes were seen following coinjection of motor neurons with pEGFP/wt and pRc/ NF-L RNA (Fig. 5B, C) or injection of a chimeric pEGFP/ NF-L RNA transgene with untranslated NF-L RNA in the 3ЈUTR (Fig. 3C) . Low-level expression of pRc/NF-L/ A680/c-myc with the EGFP marker slowed progression of neuropathic changes and led to varicose swelling of neurites and irregular distribution of EGFP fluorescence in neurites, perikarya, and nuclei (Fig. 5D) . Perikaryal alterations included vacuolization (Fig. 5D, arrows) as well as irregular aggregation of EGFP fluorescence in perikarya and nuclei (Fig. 5D, E) . End-stage degeneration resulted in disintegration and detachment of targeted motor neurons from the substrate of the culture.
Microinjection of sensory neurons in spinal cord cultures with untranslated NF-L RNA in a chimeric EGFP transgene (pEGFP/NF-L RNA) or pRc expression vector (pRc/NF-L RNA) did not lead to neurodegenerative changes. Instead, EGFP fluorescence continued to delineate the round to oval perikarya, unipolar neuritic extension, and long, thin, frequently bifurcating neuritic processes of sensory neurons (Fig. 5F ).
Specificity of RNA-Mediated Motor Neuron Degeneration
When motor and sensory neurons in the same culture were microinjected with pEGFP/NF-L RNA, persistence of EGFP fluorescence in sensory neurons contrasted with progressive degeneration and loss of targeted motor neurons. Whereas similar patterns of EGFP fluorescence from pEGFP/NF-L RNA (Fig. 6D ) and pEGFP/wt (Fig.  6C) were observed in sensory neurons, targeted motor neurons showed extensive degenerative changes following microinjection of pEGFP/NF-L RNA (Fig. 6B) , compared to pEGFP/wt control (Fig. 6A) . Quantitative analyses of motor (MN) and sensory (DRG) neuron viability following microinjection of pEGFP/wt and pEGFP/NF-L RNA showed that expression of pEGFP/NF-L RNA led to a selective loss of motor neurons (Fig. 6E) . The findings indicated a specificity of RNA-mediated neurodegenerative changes for cultured motor neurons.
EGFP Immunoreactivity in Degenerating Motor Neurons
Examination of EGFP immunoreactivity in fixed tissues enabled detection of denatured EGFP protein lacking EGFP fluorescence (38) as well as nondenatured fluorescent EGFP protein. Coinjection of pEGFP/wt and empty pRc/CMV expression vector (pRc/wt) led to widespread immunoreactivity outlining perikarya and neurites of targeted motor neuron, amidst a background of hematoxylin-stained neuronal and nonneuronal cells (Fig.  7A) . Coinjection of pEGFP/wt and pRc/CMV vector containing unmodified (pRc/NF-L RNA) or modified (pRc/ NF-L RNA/c-myc) untranslated NF-L sequence led to aggregation of anti-EGFP immunoreactivity in neurites, perikarya, and nuclei of degenerating neurons (Fig. 7B-D) . Anti-EGFP immunoreactivity appeared as multiple punctate aggregates that were irregularly scattered along linear trajectories of neuritic processes (Fig. 7B , arrowheads) or clustered in varicose enlargements of neurites (Fig. 7C, arrowheads) . In both instances, the size and clustering of punctate aggregates had a similar appearance whether or not continuity between neurite and perikarya could be demonstrated. Larger and more irregular anti-EGFP aggregates occurred in perikarya and nuclei (Fig. 7B-D) . Perikaryal aggregates tended to coalesce in a perinuclear location and obscure the recognition of nuclear aggregates. Nuclear accumulations of anti-EGFP immunoreactivity increased over time. Persistence of nuclear anti-EGFP was often observed as the final vestige of degenerated targeted motor neurons (Fig. 7D) . Coinjection of pRc/NF-L RNA/c-myc or pRc/NF-L RNA caused similar alterations, although coinjection of pRc/ NF-L RNA/c-myc was associated with increased vacuolization in perikarya (Fig. 7C, D, arrows) as well as enhanced anti-EGFP immunoreactivity in nuclei (Fig.  7D) . Perikaryal vacuoles could be seen in fixed (Fig. 7C) and unfixed (Fig. 5D ) preparations of the same neuron.
Ubiquitin Immunoreactivity in Degenerating Motor Neurons
The distribution of ubiquitin in targeted motor neurons was assessed by examining Texas Red-coupled anti-ubiquitin immunofluorescence. Aggregates of antiubiquitin immunoreactivity occurred in neurites, perikarya, and nuclei of degenerating motor neurons following coinjection of pEGFP/wt with pRc/NF-L RNA (Fig.   8 ) or pRc/NF-L RNA/c-myc (Fig. 9) . Punctate aggregates of anti-ubiquitin immunoreactivity appeared in varicose enlargements of neurites and in the adjoining perikarya of degenerating motor neurons (Fig. 8C, D arrowheads). The punctate aggregates did not colocalize with EGFP fluorescence but resembled the distribution of punctate anti-EGFP immunoreactivity in similar varicose enlargements of neurites (Fig. 7B) . Larger and more irregular aggregates of anti-ubiquitin immunoreactivity were also present in swollen neurites (Fig. 8A,  C, brackets) .
Perikarya of degenerating motor neurons often contained large confluent anti-ubiquitin aggregates in a perinuclear distribution (Fig. 8C, arrows) , a localization confirmed by comparing unmerged images (Fig. 8C) with merged images of DAPI-stained nuclei (Fig. 8D) . Accumulations of ubiquitinated aggregates around nuclei were accompanied by and often obscured by nuclear ubiquitination. Enhanced nuclear ubiquitination occurred during the latter stages of motor neuron degeneration, more so following coinjection of pRc/NF-L RNA/c-myc (Fig. 9C,  D) than pRc/NF-L RNA (Fig. 8C, D) . Increased nuclear ubiquitination was associated with increased nuclear EGFP fluorescence (Figs. 8A, B, 9A , B) and nuclear anti-EGFP immunoreactivity (Fig. 7B-D) .
Only limited amounts of perikaryal anti-ubiquitin immunofluorescence were observed in noninjected motor neurons (Fig. 9B, D) or in nonneuronal cells (Fig. 8B,  D, asterisks) . Increased anti-ubiquitin immunofluorescence was not observed in motor neurons following coinjection of pEGFP/wt with an empty pRc/CMV vector (data not shown).
DISCUSSION
The present study provides direct demonstration and unequivocal evidence for an RNA-mediated component in the pathogenesis of a neurodegenerative state. Precedence for an RNA-mediated neuropathic effect derives from studies of trinucleotide repeat diseases (reviewed in [39] [40] [41] . Expanded CUG or CAG repeats form stable hairpin structures that may either interfere with the processing of primary transcripts or interact with and alter the activities of RNA-binding proteins. Several factors with enhanced binding to expanded CUG repeats have been implicated in RNA-mediated neurodegeneration (42) (43) (44) (45) . The most compelling evidence for an RNA toxic gain-of-function derives from studies of expanded CUG repeats in the 3ЈUTR of the DMPK gene at the DM1 locus on chromosome 19q13.3. Expression of this expanded repeat in the 3ЈUTR of a heterologous actin transgene reproduced the myotonia of myotonic dystrophy in transgenic mice (46) . The complex phenotype of myotonic dystrophy can also arise from expression of expanded CCTG repeats in intron 1 of the ZNF9 gene at the DM2 locus on chromosome 3q21 (47) . Moreover, DMPK and ZNF9 transcripts with expanded CUG and CCUG repeats accumulate in nuclear foci (47) (48) (49) (50) (51) and colocalize with the same RNA-binding proteins (51, 52) .
The present study indicates that RNA-mediated, gainof-adverse effects are not limited to trinucleotide repeat diseases, but also result from expression of untranslated NF-L RNA in neurons-at-risk. motor neurons expressing a chimeric EGFP transgene, it is also apparent that the presence of NF-L sequence in the 3ЈUTR does not prevent transcription, export, or translation, nor seriously impair the stability of the chimeric transcript. The simplest interpretation of dose-dependency would favor adverse effects arising from interaction with RNA-binding factors or cofactors, either in the nuclear or cytoplasmic compartments. Alterations of cognate binding factors could account for the trans-acting adverse effects of NF-L RNA.
Expression of untranslated NF-L RNA leads to profound neurological dysfunction but limited pathological changes in motor neurons of transgenic mice (19) , similar to phenomena reported in mice expressing transgenes with expanded trinucleotide repeats (53, 54) . Expression of the same untranslated NF-L RNA causes a progression of neuropathological changes in cultured motor neurons that may not be attained or tolerated in mice but may relate to the disparity between functional and structural changes of RNA-mediated neurotoxicity in live animals. Early neuropathic changes in distal neurites, as observed in cultured motor neurons, could impair impulse transmission and account for atrophy of L4/ L5 motor nerve fibers with relative preservation of neuronal perikarya (19) . Similar atrophy of motor nerve fibers occurs in other forms of NF-induced motor neuron degeneration (3, 55, 56) and has been correlated with defective axonal transport (57) . Motor neurons may also be susceptible to alterations of a component in axonal transport (58) or to a point mutation in tubulin-specific chaperone E (59), although it is unclear how a defect in axonal transport is specific for motor neurons.
The full range of neuropathological changes manifested in cultured motor neurons also provides insights into the nature of RNA-mediated toxicity. It is particularly noteworthy that the progression of RNA-mediated toxicity in motor neurons reproduces neuropathological features of neurodegenerative diseases, such as the activation of the ubiquitin/proteasome pathway and the formation of ubiquitinated aggregates in cytoplasm and nuclei (39, 60) . The ability of RNA to trigger the same neurodegenerative changes raises the possibility that RNA or RNA-binding proteins may contribute to the underlying pathology. RNA is strongly implicated in the formation of ubiquitinated intranuclear inclusions due to premutation range expansions of CGG repeats in the FMR1gene of patients (61) and mice (62) with the cerebellar tremor/ataxia syndrome.
The resemblance of neuropathological changes to alterations in polyglutamine diseases is of particular interest. In the latter instances, ubiquitinated nuclear inclusions containing expanded polyglutamine sequence are neuropathological hallmarks of disease. Nuclear import of mutant protein is essential for neuropathic effects (63) (64) (65) (66) but the mechanisms of neurotoxicity are still unclear. Ubiquitination and association of aggregated proteins with molecular chaperones reduce the toxicity of mutant proteins and are likely to reflect protective events (63, 64, 67, 68) . Interactions of mutant proteins with transcriptional factors or cofactors have been described (69) (70) (71) (72) (73) , but the specificity of the proposed interactions has not been clearly confirmed in neurons-at-risk (74) . It is also suggested that hairpin RNA structure (40) and cognate RNA-binding proteins (75) may contribute to the pathogenesis of polyglutamine disease. Suppressor screens have identified multiple genes, including RNAbinding proteins, which reduce toxicity in models of polyglutamine disease (76) .
The ability of NF-L RNA sequence to trigger formation of ubiquitinated aggregates in cytoplasm and nuclei of degenerating motor neurons provides a novel perspective of the nature of neurodegeneration. The formation of multiple small ubiquitinated foci in proximal neurites and perikarya suggests that the neuropathic effects of NF-L RNA may originate in the cytoplasm and arise from abnormal interactions among cytoplasmic constituents. The association of EGFP protein with ubiquitinated aggregates could reflect convergence of EGFP protein onto abnormal protein aggregates. Loss of EGFP fluorescence with retention of EGFP immunoreactivity has been attributed to denaturation of EGFP protein associated with ubiquitinated aggregates (38) . Progression of neuropathological changes appears to be associated with perinuclear and nuclear localizations of enlarged ubiquitinated aggregates, similar to changes observed in other neurodegenerative diseases (39, 60) . The ability of nuclear localization signals (NLS) to translocate large polyglutamine aggregates into nuclei (38) raises the possibility that RNA-mediated aggregates may also incorporate functional NLS-containing substrates or cofactors. The marked increase in nuclear ubiquitination and accompanying redistribution of EGFP protein from perikarya into nuclei of degenerating motor neurons favors an underlying alteration in movements of substrates across nuclear membranes.
The importance of RNA-binding proteins in regulating the processing of mRNA and flow of genetic information has recently been emphasized (77, 78) . RNA-protein complexes also provide a strategic site where interactions with cellular constituents can regulate and coordinate gene expression, including gene products necessary to maintain a differentiated state (79) . Interactions among nucleic acid and protein components in cytoplasm and nucleus are critical determinants for transporting RNAprotein complexes through nuclear pores and for providing essential substrates for regulating and maintaining gene expression. It is tempting to speculate that RNAprotein complexes may be sites of vulnerability whereby aberrant expression of RNA sequence may trigger disruptive interactions among constituent components. Such abnormal interactions could give rise to protein aggregation and ubiquitination and lead to alteration or depletion of essential substrates. RNA-protein complexes may also comprise target sites of vulnerability whereby neuropathic effects may be mediated or modulated by interactions of RNA or protein components. Such RNA-protein interactions could account for the ability of altered NF-L expression, as an RNA-mediated event, to modulate the neuropathic effects of mutant SOD-1 (5, 7, 80), mutant tau (8) , and overexpression of peripherin (6) in transgenic mice. Differences in RNA-protein complexes among subsets of neurons could also explain the remarkable specificity of neurodegenerative conditions. RNAmediated neuropathic effects of NF-L provide a paradigm for identifying relevant neuropathic elements and factors leading to motor neuron degeneration.
